QRG Capital Management Inc. Sells 75,094 Shares of AbbVie Inc. $ABBV

QRG Capital Management Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 25.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 225,656 shares of the company’s stock after selling 75,094 shares during the period. AbbVie comprises 0.6% of QRG Capital Management Inc.’s holdings, making the stock its 23rd largest holding. QRG Capital Management Inc.’s holdings in AbbVie were worth $52,248,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in ABBV. Evergreen Capital Management LLC raised its position in shares of AbbVie by 6.4% during the third quarter. Evergreen Capital Management LLC now owns 52,578 shares of the company’s stock worth $12,174,000 after acquiring an additional 3,178 shares during the last quarter. Confluence Wealth Services Inc. increased its position in AbbVie by 4.7% during the 3rd quarter. Confluence Wealth Services Inc. now owns 24,429 shares of the company’s stock valued at $5,656,000 after purchasing an additional 1,097 shares during the period. First National Advisers LLC increased its position in AbbVie by 5.1% during the 3rd quarter. First National Advisers LLC now owns 23,546 shares of the company’s stock valued at $5,451,000 after purchasing an additional 1,133 shares during the period. Richardson Financial Services Inc. raised its holdings in AbbVie by 9.9% during the 3rd quarter. Richardson Financial Services Inc. now owns 1,655 shares of the company’s stock worth $383,000 after purchasing an additional 149 shares during the last quarter. Finally, Pinnacle Financial Partners Inc lifted its position in shares of AbbVie by 5.6% in the 3rd quarter. Pinnacle Financial Partners Inc now owns 181,236 shares of the company’s stock worth $41,963,000 after purchasing an additional 9,680 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ABBV. UBS Group reiterated a “neutral” rating on shares of AbbVie in a report on Tuesday. Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Morgan Stanley boosted their price target on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. BMO Capital Markets reiterated an “outperform” rating and set a $258.00 price target on shares of AbbVie in a research note on Thursday. Finally, Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $247.84.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Trading Down 1.1%

NYSE:ABBV opened at $214.38 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm’s 50 day moving average is $226.80 and its 200 day moving average is $216.28. The stock has a market capitalization of $378.89 billion, a PE ratio of 162.41, a price-to-earnings-growth ratio of 0.89 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 496.97%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.